Many are not specific to the cancer because they are altered in other malignant or benign conditions. Circulating biomarkers have a major role in this effort. contributed equally to this study.Ī key component of cancer control is screening, and significant research is underway to develop highly sensitive and specific tests that are minimally invasive. contributed equally to this article as joint last authors. Skates, Massachusetts General Hospital and Harvard Medical School, Boston, MA and Ian Jacobs, UNSW Australia, Sydney, NSW, Australia. Murdoch, St Michael's Hospital, Bristol Stephen Dobbs, Belfast City Hospital, Belfast Simon Leeson, Llandudno Hospital, Ysbyty Gwynedd Derek Cruickshank, James Cook University Hospital, Middlesbrough Lesley Fallowfield, University of Sussex, Falmer, United Kingdom Steven J. Seif, St Mary's Hospital, Manchester Howard Jenkins and Ian Scott, Royal Derby Hospital, Derby Robert Woolas, Queen Alexandra Hospital, Portsmouth John B. Amso, Cardiff University, Cardiff Keith Godfrey, Queen Elizabeth Hospital, Gateshead Alberto Lopes, Royal Cornwall Hospital, Truro Jonathan Herod, Liverpool Women's Hospital, Liverpool Karin Williamson, Nottingham City Hospital, Nottingham Mourad W.
Usha Menon, Andy Ryan, Jatinderpal Kalsi, Aleksandra Gentry-Maharaj, Mariam Habib, Sophia Apostolidou, Matthew Burnell, Susan Davies, Richard Gunu, Martin Widschwendter, Elizabeth Benjamin, Mahesh Parmar, and Ian Jacobs, University College London Anne Dawnay and Tim Mould, University College London Hospital Naveena Singh, Barts and the London School of Medicine and Dentistry David Oram and Karina Reynolds, St Bartholomew's Hospital Alistair McGuire, London School of Economics Stuart Campbell, Create Health Clinic Aarti Sharma, University Hospital of Wales Nazar N.